SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.6B
Q4 2021
Positions
71
Filings on Record
27
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Boxer Capital, LLC reported $2.6B in U.S.-listed holdings across 71 positions for Q4 2021.

Its largest position, MRTXEUR, represents 11.4% of the portfolio.

Compared with Q3 2021, the fund opened 7 new positions and exited 24.

Portfolio Metrics

Turnover
+21.6%
vs prior filed quarter
Top-10 Concentration
+55.8%
share of reported value
Largest Position
+11.4%
Mirati Therapeutics
New / Exited
7 / 24
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 73.7%Other: 10.9%ETP: 9.6%ADR: 5.8%Equity WRT: 0.0%
  • Common Stock · 73.7% · $1.9B
  • Other · 10.9% · $280M
  • ETP · 9.6% · $246M
  • ADR · 5.8% · $150M
  • Equity WRT · 0.0% · $504,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR SER TRNEW+2.20M2.20M+$246M$246M
SPDR SER TRNEW+550.0K550.0K+$62M$62M
FATEFate Therapeutics Inc.NEW+500.0K500.0K+$29M$29M
RAREUltragenyx Pharmaceutical Inc.NEW+200.0K200.0K+$17M$17M
Theseus Pharmaceuticals Inc.NEW+892.1K892.1K+$11M$11M
EQRX Inc.NEW+1.00M1.00M+$7M$7M
ACADAcadia Pharmaceuticals Inc.NEW+185.0K185.0K+$4M$4M
RLAYRelay Therapeutics Inc.ADDED+1.38M2.67M+$41M$82M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMirati Therapeutics Inc.history →COM11.39%$293M2.00M
2SPDR SER TRS&P BIOTECH9.57%$246M2.20M
32662247DiTeos Therapeutics Inc.history →COM7.86%$202M4.35M
4ONCBeiGene Ltdhistory →SPONSORED ADR5.26%$135M500.0K
5SWTXUSDSpringworks Therapeutics Inc.history →COM5.00%$129M2.08M
6CYTKCytokinetics Inc.history →COM NEW3.72%$96M2.10M
7TYRATyra Biosciences Inchistory →COM3.52%$91M6.45M
8RVMDRevolution Medicines Inc.history →COM3.41%$88M3.48M
9RLAYRelay Therapeutics Inc.history →COM3.18%$82M2.67M
10TNGXTango Therapeutics inchistory →COM2.92%$75M6.87M
11PMVPPMV Pharmaceuticals Inc.history →COM2.55%$66M2.84M
12Merus NVCOM2.35%$60M1.90M
13RCUSArcus Biosciences Inc.history →COM2.25%$58M1.43M
142655787DBlueprint Medicines Corphistory →COM2.11%$54M507.4K
15IDYAIdeaya Biosciences Inc.history →COM2.02%$52M2.20M
16SG7Sage Therapeutics Inc.history →COM1.81%$47M1.09M
17ANABAnaptys Bio Inc.history →COM1.75%$45M1.30M
18NUVBNuvation Bio Inc.history →COM CL A1.43%$37M4.34M
19NRIXNurix Therapeutics Inc.history →COM1.38%$35M1.22M
20KNTEUSDKinnate Biopharma Inc.history →COM1.27%$33M1.85M
21RCKTRocket Pharmaceuticals Inc.history →COM1.24%$32M1.47M
22FATEFate Therapeutics Inc.history →COM1.14%$29M500.0K
23GOSSGossamer Bio Inc.history →COM1.08%$28M2.46M
24AM6Amicus Therapeutics Inc.history →COM1.04%$27M2.33M
25RNAGBPAvidity Biosciences Inc.history →COM1.04%$27M1.12M
26BLUBellus Health Inc.history →COM NEW1.00%$26M3.20M
27GH Research PLCORDINARY SHARES0.92%$24M1.01M
28NUVLNuvalent Inchistory →COM0.89%$23M1.21M
29IOVAIovance Biotherapeutics Inchistory →COM0.82%$21M1.10M
30DAWNGBXDay One Biopharmaceuticals Inc.history →COM0.78%$20M1.19M
31XENEXenon Pharmaceuticals Inc.history →COM0.73%$19M600.0K
32Aligos Therapeutics Inc.COM0.70%$18M1.53M
33AKROAkero Therapeutics Inc.history →COM0.68%$18M831.5K
34RAREUltragenyx Pharmaceutical Inc.history →COM0.65%$17M200.0K
35CGEMCullinan Oncology Inc.history →COM0.64%$17M1.07M
36Rain Therapeutics Inc.COM0.59%$15M1.18M
37Prothena Corporation PLCSHS0.58%$15M300.0K
38MISTMilestone Pharmaceuticals Inc.history →COM0.57%$15M2.24M
39260Centessa Pharmaceuticals PLChistory →SPONSORED ADS0.55%$14M1.25M
40Point Biopharma Global IncCOM0.54%$14M2.50M
41BCABGBPBioAtla Inc.history →COM0.52%$13M686.3K
42Theseus Pharmaceuticals Inc.COM0.44%$11M892.1K
43BDTXBlack Diamond Therapeutics Inc.history →COM0.42%$11M2.01M
44Selecta Biosciences Inc.COM0.42%$11M3.28M
45EPIEUREssa Pharma Inc.history →COM NEW0.40%$10M724.5K
4632WCodiak Biosciences Inc.COM0.37%$9M850.1K
47NGM Biopharmaceuticals Inc.COM0.34%$9M500.0K
48BMEABiomea Fusion Inc.COM0.34%$9M1.19M
49MEI Pharma Inc.COM NEW0.30%$8M2.91M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.